Back to Search Start Over

Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Authors :
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire
Devereaux, P.J.
Marcucci, Maura
Painter, Thomas W.
Conen, David
Lomivorotov, Vladimir
Sessler, Daniel I.
Chan, Matthew T.V.
Borges, Flavia K.
Martínez-Zapata, María J.
Wang, Chew Yin
Xavier, Denis
Ofori, Sandra N.
Wang, Michael K.
Efremov, Sergey
Landoni, Giovanni
Kleinlugtenbelt, Ydo V.
Szczeklik, Wojciech
Schmartz, Denis
Garg, Amit X.
Short, Timothy G.
Wittmann, Maria
Meyhoff, Christian S.
Amir, Mohammed
Torres, David
Patel, Ameen
Duceppe, Emmanuelle
Ruetzler, Kurt
Parlow, Joel L.
Tandon, Vikas
Fleischmann, Edith
Polanczyk, Carisi A.
Lamy, Andre
Astrakov, Sergey V.
Rao, Mangala
Wu, William K.K.
Bhatt, Keyur
de Nadal, Miriam
Likhvantsev, Valery V.
Paniagua, Pilar
Aguado, Hector J.
Whitlock, Richard P.
McGillion, Michael H.
Prystajecky, Michael
Vincent, Jessica
Eikelboom, John
Copland, Ingrid
Balasubramanian, Kumar
Turan, Alparslan
Bangdiwala, Shrikant I.
Stillo, David
Gross, Peter L.
Cafaro, Teresa
Alfonsi, Pascal
Roshanov, Pavel S.
Belley-Côté, Emilie P.
Spence, Jessica
Richards, Toby
VanHelder, Tomas
McIntyre, William
Guyatt, Gordon
Yusuf, Salim
Leslie, Kate
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire
Devereaux, P.J.
Marcucci, Maura
Painter, Thomas W.
Conen, David
Lomivorotov, Vladimir
Sessler, Daniel I.
Chan, Matthew T.V.
Borges, Flavia K.
Martínez-Zapata, María J.
Wang, Chew Yin
Xavier, Denis
Ofori, Sandra N.
Wang, Michael K.
Efremov, Sergey
Landoni, Giovanni
Kleinlugtenbelt, Ydo V.
Szczeklik, Wojciech
Schmartz, Denis
Garg, Amit X.
Short, Timothy G.
Wittmann, Maria
Meyhoff, Christian S.
Amir, Mohammed
Torres, David
Patel, Ameen
Duceppe, Emmanuelle
Ruetzler, Kurt
Parlow, Joel L.
Tandon, Vikas
Fleischmann, Edith
Polanczyk, Carisi A.
Lamy, Andre
Astrakov, Sergey V.
Rao, Mangala
Wu, William K.K.
Bhatt, Keyur
de Nadal, Miriam
Likhvantsev, Valery V.
Paniagua, Pilar
Aguado, Hector J.
Whitlock, Richard P.
McGillion, Michael H.
Prystajecky, Michael
Vincent, Jessica
Eikelboom, John
Copland, Ingrid
Balasubramanian, Kumar
Turan, Alparslan
Bangdiwala, Shrikant I.
Stillo, David
Gross, Peter L.
Cafaro, Teresa
Alfonsi, Pascal
Roshanov, Pavel S.
Belley-Côté, Emilie P.
Spence, Jessica
Richards, Toby
VanHelder, Tomas
McIntyre, William
Guyatt, Gordon
Yusuf, Salim
Leslie, Kate
Source :
New England Journal of Medicine, Vol. 386, no.21, p. 1986-1997 (2022)
Publication Year :
2022

Abstract

BACKGROUND Perioperative bleeding is common in patients undergoing noncardiac surgery. Tranexamic acid is an antifibrinolytic drug that may safely decrease such bleeding. METHODS We conducted a trial involving patients undergoing noncardiac surgery. Patients were randomly assigned to receive tranexamic acid (1-g intravenous bolus) or placebo at the start and end of surgery (reported here) and, with the use of a partial factorial design, a hypotension-avoidance or hypertension-avoidance strategy (not reported here). The primary efficacy outcome was life-threatening bleeding, major bleeding, or bleeding into a critical organ (composite bleeding outcome) at 30 days. The pri- mary safety outcome was myocardial injury after noncardiac surgery, nonhemor- rhagic stroke, peripheral arterial thrombosis, or symptomatic proximal venous thromboembolism (composite cardiovascular outcome) at 30 days. To establish the noninferiority of tranexamic acid to placebo for the composite cardiovascular out- come, the upper boundary of the one-sided 97.5% confidence interval for the hazard ratio had to be below 1.125, and the one-sided P value had to be less than 0.025. RESULTS A total of 9535 patients underwent randomization. A composite bleeding outcome event occurred in 433 of 4757 patients (9.1%) in the tranexamic acid group and in 561 of 4778 patients (11.7%) in the placebo group (hazard ratio, 0.76; 95% confi- dence interval [CI], 0.67 to 0.87; absolute difference, −2.6 percentage points; 95% CI, −3.8 to −1.4; two-sided P<0.001 for superiority). A composite cardiovascular outcome event occurred in 649 of 4581 patients (14.2%) in the tranexamic acid group and in 639 of 4601 patients (13.9%) in the placebo group (hazard ratio, 1.02; 95% CI, 0.92 to 1.14; upper boundary of the one-sided 97.5% CI, 1.14; absolute difference, 0.3 per- centage points; 95% CI, −1.1 to 1.7; one-sided P=0.04 for noninferiority). CONCLUSIONS Among patients undergoing noncardiac surgery, the incidence of the com

Details

Database :
OAIster
Journal :
New England Journal of Medicine, Vol. 386, no.21, p. 1986-1997 (2022)
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1372956897
Document Type :
Electronic Resource